TEMFERON clinical trials

An open-label phase 1/2 study to evaluate the safety, biological response and efficacy of a single dose of Temferon (autologous CD34+-enriched hematopoietic stem and progenitors cells genetically modified with human Interferon-α2) in patients with metastatic renal cell carcinoma

This study is testing a new treatment called Temferon for advanced kidney cancer that has spread. It checks if Temferon is safe, how the body reacts to it, and how well it works in people who have already tried standard treatments.